Novartis and Oxford University begin R&D tie-upNovartis and Oxford University have begun a partnership that will attempt to use artificial intelligence to predict how Share XNovartis and Oxford University begin R&D tie-uphttps://pharmaphorum.com/news/novartis-and-oxford-university-begin-rd-tie-up/
Alkermes/Biogen hope for less tummy trouble with new MS pillAlkermes and Biogen have filed a new multiple sclerosis pill with the FDA, which they hope will treat Share XAlkermes/Biogen hope for less tummy trouble with new MS pillhttps://pharmaphorum.com/news/alkermes-biogen-hope-for-less-tummy-trouble-with-new-ms-pill/
Roche beats revenue forecasts as sales of old drugs take off in ChinaRoche has beaten analysts’ revenue forecasts in the third quarter, after mounting sales of its older drugs in Share XRoche beats revenue forecasts as sales of old drugs take off in Chinahttps://pharmaphorum.com/news/roche-beats-revenue-forecasts-as-sales-of-old-drugs-take-off-in-china/
Merck KGaA’s BTK drug reduces lesions in relapsing MS patientsGermany’s Merck KGaA has said it is “encouraged” by mid-stage trial results showing that its Bruton’s kinase (BTK) Share XMerck KGaA’s BTK drug reduces lesions in relapsing MS patientshttps://pharmaphorum.com/news/merck-kgaas-btk-drug-reduces-lesions-in-relapsing-ms-patients/
Roche unveils long-term data from MS blockbuster OcrevusPeople with relapsing multiple sclerosis treated sooner with Roche’s Ocrevus saw a faster reduction in disease activity and Share XRoche unveils long-term data from MS blockbuster Ocrevushttps://pharmaphorum.com/news/roche-unveils-long-term-data-from-ms-blockbuster-ocrevus/
Novartis chases untapped MS market with siponimodUS and European regulators have accepted filings for Novartis’s siponimod for secondary progressive multiple sclerosis (SPMS). The US Share XNovartis chases untapped MS market with siponimodhttps://pharmaphorum.com/news/novartis-chases-untapped-ms-market-with-siponimod/
Collaboration can ensure access to life-changing innovationAs a pioneering risk sharing scheme has shown, new medications can be the catalyst for a whole new Share XCollaboration can ensure access to life-changing innovationhttps://pharmaphorum.com/views-analysis-market-access/access-life-changing-innovation-risk-sharing-scheme/
Listening to the Patient Voice: seek out the quietest voice to meet the biggest needThe success or failure of patient centricity rests on getting the patient voice in the mix – not Share XListening to the Patient Voice: seek out the quietest voice to meet the biggest needhttps://pharmaphorum.com/views-analysis-patients/listening-patient-voice/
MS campaigner Trishna Bharadia scoops Woman of the Year awardMultiple sclerosis campaigner Trishna Bharadia has been named Woman of the Year at the 2018 Asian Achievers Awards Share XMS campaigner Trishna Bharadia scoops Woman of the Year awardhttps://pharmaphorum.com/news/ms-campaigner-trishna-bharadia-scoops-woman-of-the-year-award/
